PYRROLOPYRIDINEAMINO DERIVATIVES AS MPS1 INHIBITORS

The present invention relates to the use of certain pyrrolopyridineamino derivatives (hereinafter referred to as "PPA derivatives"), particularly 1H-pyrrolo[3,2-c]pyridine-6- amino derivatives, to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 - also known as TTK) kinases e...

Full description

Saved in:
Bibliographic Details
Main Authors ATRASH, BUTRUS, NAUD, SEBASTIEN GASTON ANDRE, SHELDRAKE, PETER WILLIAM, BLAGG, JULIAN, BAVETSIAS, VASSILIOS
Format Patent
LanguageEnglish
French
Published 20.09.2012
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to the use of certain pyrrolopyridineamino derivatives (hereinafter referred to as "PPA derivatives"), particularly 1H-pyrrolo[3,2-c]pyridine-6- amino derivatives, to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 - also known as TTK) kinases either directly or indirectly via interaction with the Mps kinase itself. In particular, the present invention relates to PPA derivatives for use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of the PPA derivatives, and pharmaceutical compositions comprising them. Formula (I) La présente invention concerne l'utilisation de certains dérivés pyrrolopyridineamino (ci-après rapportés en tant que «dérivés PPA»), en particulier les dérivés 1H-pyrrolo[3,2-c]pyridine-6-amino, pour inhiber la fonction de checkpoint du fuseau des Monofuseaux 1 (Mps1 - aussi connues comme TTK) kinases soit directement soit indirectement via l'interaction avec la Mps kinase elle-même. En particulier, la présente invention concerne des dérivés PPA pour l'utilisation en tant qu'agents thérapeutiques pour le traitement et/ou la prévention de maladies prolifératives, comme le cancer. La présente invention concerne aussi les procédés pour la préparation des dérivés PPA derivatives, et des compositions pharmaceutiques les comprenant. Formule (I)
Bibliography:Application Number: WO2012GB50564